Ameritas Investment Partners’s Lexeo Therapeutics LXEO Stock Holding History

Ameritas Investment Partners’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.8K	Hold	5,121	–	–	﹤0.01%	2666
2026 Q1	$29.4K	Hold	5,121	–	–	﹤0.01%	2407
2025 Q4	$50.9K	Buy	5,121 +2,734	+115%	+$24.9K	﹤0.01%	2104
2025 Q3	$15.8K	Hold	2,387	–	–	﹤0.01%	2773
2025 Q2	$9.6K	Hold	2,387	–	–	﹤0.01%	2993
2025 Q1	$8.28K	Hold	2,387	–	–	﹤0.01%	2874
2024 Q4	$15.7K	Hold	2,387	–	–	﹤0.01%	2730
2024 Q3	$21.6K	Buy	2,387 +1,364	+133%	+$16.3K	﹤0.01%	2617
2024 Q2	$16.4K	Hold	1,023	–	–	﹤0.01%	2701
2024 Q1	$16K	Buy	+1,023	New	+$16K	﹤0.01%	2653

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Ameritas Investment Partners's LXEO Position: Q2 2026 in Review

Ameritas Investment Partners held its Lexeo Therapeutics (LXEO) position steady in Q2 2026 at 5,121 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2666.

Ameritas Investment Partners first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. The position peaked at $50.9K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Ameritas Investment Partners held 5,121 shares of Lexeo Therapeutics worth $23.8K as of Q2 2026.
Ameritas Investment Partners left its Lexeo Therapeutics share count unchanged in Q2 2026.
Lexeo Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2666 holding.
Ameritas Investment Partners first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
Ameritas Investment Partners's Lexeo Therapeutics position peaked at $50.9K in Q4 2025.
141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.